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It has been suggested that Id-1 has a critical role in the tumour progression and aggressiveness of several human cancers. However,
the clinicopathological and biological significance of Id-1 overexpression remains unclear in human primary cancer. To investigate the
association between Id-1 expression and cell proliferation or tumour angiogenesis, we examined the cell cycle kinetic indices (the
proliferation and apoptotic indices, PI and AI) and intratumoral microvessel density (MVD) in 65 human pancreatic cancers. We also
investigated the relationship between its expression and various clinicopathological factors to determine the clinical significance of Id-
1 overexpression. Out of a total 65 cases, 32 (49.3%) showed overexpression of Id-1 vs normal tissues. Id-1 expression was found to
be significantly associated with MVD (P¼0.002). In further analysis of subgroups with higher and lower Id-1 expression, tumours with
higher Id-1 expression (scores 4 and 5) showed significantly higher MVD than tumours with lower expression of Id-1 (scores 2 and 3)
(111.18757.14 vs 64.13728.19, Po0.001). However, no significant association was found between Id-1 overexpression and patient
survival rate. No significant association was also found between Id-1 expression and cell cycle kinetic indices (PI or AI) in pancreatic
cancer. Moreover, the overexpression of Id-1 protein was not correlated with any significant clinicopathologic factors. These findings
indicate that Id-1 overexpression is closely related with tumour angiogenesis and a higher density of intratumoral vessel, but that it is
not associated with a poorer prognosis of survival or a higher cell proliferative potential in human pancreatic cancer.
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Id proteins (inhibitors of differentiation or DNA binding) are
members of a family of basic helix–loop–helix (bHLH) transcrip-
tion factors lacking the DNA-binding domain. Therefore, they act
as dominant-negative regulators of basic HLH proteins by forming
transcriptionally inactive Id-bHLH protein complexes (Riechmann
et al, 1994; Riechmann and Sablitzky, 1995). Id proteins play key
roles in the regulation of cell differentiation during neurogenesis,
lymphoiesis and angiogenesis. Their functions also include the
promotion of cell growth and cell cycle progression, and apoptotic
induction (Lyden et al, 1999; Norton, 2000).
Recently, several reports have shown that Id-1 protein can
induce cell proliferation and increase DNA synthesis, and that it
can immortalise mammalian cells in cooperation with other
oncogenes (Norton and Atherton, 1998; Alani et al, 1999). Id-1
overexpression has been found in several types of primary human
cancers including breast, pancreatic, prostate, melanoma and
cervical cancers (Maruyama et al, 1999; Langlands et al, 2000; Lin
et al, 2000; Polsky et al, 2001; Schindl et al, 2001; Ouyang et al,
2002a; Wang et al, 2002; Schindl et al, 2003; Schoppmann et al,
2003). Moreover, the ectopic expression of Id-1 increases the
proliferation, migration, invasion and metastasis of breast cancer
cells (Desprez et al, 1998; Lin et al, 2000). In addition, Id-1 seems
to be an essential factor in the promotion of G1/S cell cycle
transition in certain cancers by inactivating of p16 and increasing
of CDK4 activity/RB (Polsky et al, 2001; Ouyang et al, 2002b; Singh
et al, 2002). These lines of evidence strongly suggest that Id
proteins play important roles not only in tumorigenesis and in
tumour progression.
Id-1 and Id-3 may induce angiogenesis by regulating the growth
and invasion of endothelial cells. They are also required for proper
angiogenesis in the neuroectoderm during mouse development
(Lyden et al, 1999; Norton, 2000). Moreover, the downregulation of
these proteins results in an angiogenic defect in growth and
metastasis of tumour xenografts (Lyden et al, 1999). Id-1 can also
induce the expression of a novel metalloproteinase of 120kDa in
breast epithelial cells (Desprez et al, 1998). These studies indicate
that Id-1 has a potential role in the aggressiveness of malignant
tumour and in formation of tumour angiogenesis.
Pancreatic cancer is one of the most aggressive malignant
tumours and is associated with the activation of various oncogenes
such as Ki-ras and the inactivation of tumour suppressor genes, for
example, p16 and p53 (Korc, 1998). Recently, Maruyama et al
demonstrated that Id-1 is significantly overexpressed in pancreatic
cancer rather than chronic pancreatitis, suggesting that Id-1
protein may be associated with the enhanced proliferative
potential of pancreatic cancer cells. However, no evidence is
available upon the prognostic implications of Id-1 in human
pancreatic cancers. Therefore, we undertook to examine Id-1
overexpression in human pancreatic cancers to determine its role
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yas a poor prognostic factor. Furthermore, we investigated its
association with intratumoral microvessel density, cell prolifera-
tion and apoptosis to clarify its role in the proliferation potential of
tumour cells and in the induction of tumour angiogenesis. Our
results show that Id-1 overexpression is significantly related with
tumour angiogenesis, higher density of intratumoral vessel, but
not associated with a poorer prognosis or a higher proliferative
potential in human pancreatic cancers. We provide the first
evidence to clarify the association between Id-1 overexpression
and tumour angiogenesis in human primary cancers and suggest
that Id-1 protein may be an important new target molecule for
antiangiogenic drugs in cancer treatment.
MATERIALS AND METHODS
Patients and tissue samples
In all, 65 pancreatic ductal adenocarcinoma cases that successfully
underwent resection at Samsung Medical Center (Seoul, Korea)
between January 1995 and September 1999 were enroled in this
retrospective study. The mean follow-up interval was 12.6 months
(range, 1–66.2 months). In total, 51 (78.5%) patients died and 14
(21.5%) patients remained alive during the follow-up period.
Haematoxylin–eosin stains were reviewed by two pathologists and
the most representative paraffin-embedded blocks were chosen for
further analysis. Histological grade was evaluated according to the
established AJCC criteria.
The clinicopathologic characteristics of the 65 patients, which
included age, bilirubin level, tumour marker (CA 19–9), location,
size, AJCC stage, differentiation, distant metastasis and survival,
were evaluated. The median age of the patients at the time of
operation was 60.4 years (range: 40–79 years). Tumours were
classified according to the location and AJCC stage based on data
obtained by clinical examination, imaging methods, operation
records and surgical specimens.
Immunohistochemical staining
Immunohistochemical staining for Id-1, Ki-67 and CD-34 was
performed by using avidin–biotin peroxidase complex method
with aminoethylcarbamazole (AEC) as chromogen using LSAB kit
(DAKO, Carpinteria, CA, USA). Paraffin-embedded tissue blocks,
which included tumour and normal pancreatic tissues, were
sectioned into 5mm. The slides were deparaffinised using xylene,
and rehydrated using graded alcohols. The slides were then
incubated in 3% hydrogen peroxide for 10min to block
endogenous peroxidase activity. Primary antibodies of Id-1 (Santa
Cruz, Santa Cruz, CA, USA), Ki-67 (Immunotech, France), and CD-
34 (Immunotech, France) were used at a dilution of 1:50. Then,
secondary biotinylated antibody and avidin–biotin complex
reagent were applied and the sections were counterstained with
haematoxylin and mounted. Because Id-1 is strongly expressed in
the smooth muscle cells of vessels, they were used as an internal
positive control in each section (Dorai and Sampath, 2001). The
Id-1 immunoreactivity shown by smooth muscle cells of blood
vessels was also used as a reference for strong immunoreactivity.
As a negative control, sections were incubated with Tris-buffered
saline containing 2% rabbit serum and 1% bovine serum albumin
instead of the primary antibody. The Id-1 immunoreactivity was
graded based on the intensity and the number of positive cells, as
described in the previous study (Maruyama et al, 1999). The
percentage of positive cancer cells was classified into four groups:
0, no tumour cells exhibiting immunoreactivity; 1, o33%
immunoreactivity; 2, 33–67% immunoreactivity; 3, 467% im-
munoreactivity. The immunohistochemical signal intensities were
also classified into four groups: 0, no immunoreactivity; 1, weak
immunoreactivity; 2, moderate immunoreactivity; 3, strong
immunoreactivity. Finally, we summed the area and the intensity
scores. The Ki-67 labelling index (Proliferation Index; PI) was
determined by counting the percentage of positive cells among
1000 tumour cells in 10 random regions in  400 fields.
Intratumoral microvessel density (MVD) was recorded by count-
ing CD-34-positive vessels in the highest vascularised area in four
 200 fields. Blood vessels with lumen diameter larger than
approximately eight red blood cells were excluded.
Detection of apoptotic cells
Cells undergoing programmed cell death (apoptosis) were detected
by in situ specific labelling of nuclear DNA fragmentation method
(TUNEL method) using ApopTag In situ apoptosis detection kit
(Oncor, Gaithersburg, MD, USA). Paraffin-embedded thin sections
(5mm) were deparaffinised and digested with 20mgml
 1 protei-
nase K (DAKO, Carpinteria, CA, USA). Endogenous peroxidase
activity was blocked with the treatment of 2.0% hydrogen peroxide
in phosphate-buffered saline (PBS) for 5min. The sections were
then incubated with working strength TdT enzyme in a humidified
chamber at 371C for 1h, rinsed with working strength stop/wash
buffer, and incubated with anti-digoxigenin peroxidase for 30min.
Diaminobenzidine (DAKO, Carpinteria, CA, USA) was applied for
colour development. The apoptotic index (AI) was calculated by
counting the percentage of TUNEL-positive tumour cells in the
light microscopic fields at  400. Necrotic and inflammatory areas
were excluded.
Statistical analysis
All statistical analyses were carried out using commercially available
software system (SPSS version 8.0, USA). All data are presented as
mean 7 standard deviation. The w
2-test and the Student’s t-test
were used to examine the association between Id-1 expression and
the various clinicopathologic characteristics including PI, AI and
MVD. The Kaplan–Meier method was used to calculate survival
curves, and the log-rank test was performed to compare the
difference in survival rates among the patient groups. A difference
of Po0.05 between the groups was considered significant.
RESULTS
Id-1 overexpression in human primary pancreatic cancer
All samples were stained for Id-1, and showed diffuse cytoplasmic
staining from moderate to strong intensity in the tumour cells
whereas the staining characteristics of normal pancreatic glands
were diffuse and weak (Figure 1). As shown in Table 1, all of the
positive cases were classified by summing area and intensity
scores: score 2, 15 cases (23.1%): score 3, 18 cases (27.7%): score 4,
20 cases (30.8%): score 5, 12 cases (18.5%). The average score of
normal pancreatic tissue was 2.070.4. Thus, tumours with scores
of 4 and 5 were considered to overexpress Id-1. In all, 32 cases
(49.3%) revealed Id-1 overexpression vs normal tissue. No
significant relationship was found between Id-1 expression and
other clinicopathologic characteristics including age, bilirubin,
tumour marker (CA 19-9), location, size, AJCC stage, differentia-
tion and distant metastasis (Table 1).
Id-1 overexpression is significantly related to angiogenesis
but is not associated with cell proliferation
To investigate the association between Id-1 expression and cell
proliferation or tumour angiogenesis, we examined PI, AI and
MVD in tumour cells using Ki-67, TUNNEL and CD34 staining,
respectively. As shown in Table 2, Id-1 expression was found to be
significantly related with tumour MVD (P¼0.002). In further
analysis of subgroups showing higher and lower Id-1 expression,
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yFigure 1 (A) Normal pancreatic tissue showing weak and focal staining for Id-1 (score 2). (B) The representative section showing Id-1expression absent
in pancreatic cancer. Inset: In the blood vessel as a positive control, Id-1 expression is weak or negative in endothelial cells, while smooth muscle cells show
strong immunoreactivity ( 400). (C, D) The representative sections showing moderate and strong Id-1 expression in pancreatic cancer, respectively. Inset:
tumour cells show mostly diffuse cytoplasmic Id-1 expression ( 400). The arrows in each picture indicate the blood vessels used as an internal positive
control.
Table 1 Relationships between Id-1 expression and the clinicopathologic characteristics of pancreatic adenocarcinomas
Id-1 expression
Score 2 (n¼15) Score 3 (n¼18) Score 4 (n¼20) Score 5 (n¼12) P-value
Age (years) 60.878.7 63.378.5 57.5711.2 60.1712.0 0.38
Male/female 9/6 14/4 11/9 6/6 0.38
Bilirubin 6.176.3 9.079.9 3.777.8 7.477.3 0.24
CA19-9 100671423 255075765 158072850 94871864 0.59
Tumour size (cm) 3.172.9 4.773.4 3.171.1 3.771.8 0.38
Location
Head 11 10 15 8
Body/tail 4 8 5 4 0.58
Tumour stage
I 3164
I I 4655
III 3 3 3 1
IV 5 8 6 2 0.66
Metastasis
Positive 5 8 6 2
Negative 10 10 14 10 0.46
Differentiation
Well 3 1 2 2
Moderated 11 13 16 9
Poorly 0 4 2 1 0.46
All data are presented as the mean7s.d.
Table 2 Relationships between Id-1 expression and proliferation index, apoptotic index and microvessel density
Id-1 expression
Score 2 (n¼15) Score 3 (n¼18) Score 4 (n¼20) Score 5 (n¼12) P-value
MVD 71.1734.1 58.3721.5 109.5758.0 110.2757.2 0.002
PI 17.578.8 18.879.8 13.8713.9 13.8711.3 0.47
AI 0.9570.87 0.6470.52 0.8870.94 0.9770.84 0.62
All data are presented as the mean7s.d. MVD¼microvessel density; PI¼proliferation index (Ki-67 stain), AI¼apoptotic index (TUNNEL stain).
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ytumours with higher Id-1 expression (scores 4 and 5) also showed
significantly higher MVD than tumours with lower Id-1 expression
(scores 2 and 3) (111.18757.14 vs 64.13728.19, Po0.001) (Figures
2 and 3). However, no significant relation was found between Id-1
expression and PI (tumour cell proliferation) or AI (tumour cell
apoptosis) (P¼0.47, 0.62, respectively) (Table 2). These results
indicate that Id-1 is significantly associated with tumour
angiogenesis in human pancreatic cancer, but that it is not related
with tumour growth via enhanced cell proliferation or apoptotic
inhibition.
Id-1 overexpression is not significantly related with a
poorer survival rate
As a positive association of Id-1 expression with tumour
angiogenesis, we examined the effect of Id-1 expression upon
clinicopathologic prognostic factors in pancreatic cancer patients.
As shown in Figure 4, Kaplan–Meier survival curves showed no
significant correlation between patient survival and Id-1 expres-
sion (P¼0.08 by log-rank test). Therefore, these results suggest
that Id-1 overexpression is not an significant indicator of a poor
prognosis in human pancreatic cancer.
DISCUSSION
Id protein is a family member of HLH transcription factors lacking
DNA binding domain that has been shown to be an important
regulator of cellular differentiation and proliferation (Norton,
2000). Id-1 overexpression has been reported in several human
primary cancers including pancreatic, breast and cervical cancers.
Evidence indicates that Id-1 may be associated with an aggressive
phenotype of human cancers (Maruyama et al, 1999; Langlands
et al, 2000; Lin et al, 2000; Polsky et al, 2001; Schindl et al, 2001;
Ouyang et al, 2002a; Wang et al, 2002). In the present study, we
observed Id-1 overexpression in human pancreatic cancer and we
also investigated the association between its expression and cell
proliferation and apoptotic indices, tumour MVD, and clinico-
pathological prognostic factors in an effort to clarify its biologic
role in human pancreatic cancers. Our data show that Id-1
expression is significantly related with tumour MVD. However, it
was not found to affect PI or AI, which are both important markers
in cell cycle kinetics. Furthermore, no significant correlation was
observed between Id-1 expression and the survival rate in
pancreatic cancer patients. Our data indicate that Id-1 expression
is closely related with tumour angiogenesis, but that it is not
related to a poorer prognostic marker in human pancreatic
cancers.
In the present study, Id-1 overexpression was found to be
significantly associated with intratumoral microvessel prolifera-
tion, indicating that Id-1 has a significant role in tumour
Figure 2 The representative sections showing the positive relation between of Id-1 expression and tumour angiogenesis (microvessel density) in pancreas
cancers using immunohistochemical staining with Id-1 and CD34 antibodies. (A, B) Id-1 and CD 34 staining, respectively, in the tumour with lower
expression (score 3). (C, D) Id-1 and CD 34 staining in the tumour with higher expression (score 5), respectively. Id-1 expression was found to be positively
related with tumour angiogenesis (higher microvessel density).
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Figure 3 Analysis of subgroups with higher or lower Id-1 expressions.
Tumours with higher Id-1 expression (scores 4 and 5) showed significantly
higher MVD than tumours with lower Id-1 expression (scores 2 and 3)
(111.18757.14 vs 64.137 28.19, Po0.001; Student’s t-test).
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receptors have been implicated with the angiogenesis (Risau,
1997). Lyden et al (1999) found that Id-1 protein is required for the
proliferation and invasion of endothelial cells during angiogenesis.
Moreover, loss of Id-1 and Id-3 also led to an unexpected defect in
angiogenesis in knockout mice. Furthermore, the overexpression
of Id-1 was shown to induce the expression of 120kDa gelatinase
in breast epithelial cells, which show an increase of invasiveness
(Desprez et al, 1998). Therefore, taken together with previous
studies, our data indicate that Id-1 is an important molecule in
tumour angiogenesis and in the aggressiveness of human cancers.
This is the first evidence that clarifies the association between Id-1
expression and tumour angiogenesis in human primary cancers. It
appears that Id-1 protein may be an important new target molecule
for antiangiogenic drug design in cancer treatment.
Several investigations have demonstrated that Id protein affects
cell growth via the mechanisms of cell proliferation and/or
apoptosis (Kim et al, 1999; Lin et al, 1999; Norton, 2000; Alani
et al, 2001). It has been suggested that Id-1 and Id-2 proteins may
function in the bHLH-mediated inactivation of the cyclin-
dependent kinase inhibitors, for example, p21
WAF1, p16
INK4a and
p27
KIP1 (Prabhu et al, 1997; Polsky et al, 2001; Ouyang et al, 2002b;
Singh et al, 2002). In addition, Id-1 expression has been observed
in small proliferating ducts and in the large ducts without
dysplastic changes of chronic pancreatitis, which again indicates
the proliferative potential of Id-1 (Maruyama et al, 1999). Thus, in
the present study, we examined the proliferative potential of Id-1
expression in human primary pancreatic cancer by investigating
the relation between its expression and the cell kinetic indices of PI
and AI. However, our data show no significant relation between Id-
1 expression and tumour cell proliferation in human primary
pancreatic cancers. Therefore, it remains unclear whether Id-1 has
a proliferative potential in human primary cancers although Id-1
has been implicated in the modulation of several cell cycle
regulators. However, its proliferative potential in other human
primary cancers remains to be clarified.
Id-1 plays a role in the early step of human carcinogenesis, for
example, in melanoma and cervical cancer, whereas id-1 expres-
sion is markedly different between in situ and invasive breast
carcinoma (Lin et al, 2000; Polsky et al, 2001; Schindl et al, 2001).
These previous studies suggest that the role of Id-1 protein in
human carcinogenesis is tissue specific. Id-1 was also found to be
overexpressed in pancreatic cancers and in dysplastic/metaplastic
ducts in chronic pancreatitis (Maruyama et al, 1999). Thus, it has
been suggested that Id-1 is one of the early markers in pancreatic
malignant transformation and that it may contribute to the early
step carcinogenesis of human pancreatic cancer. In several human
solid tumours, Id-1 overexpression has been reported to be an
independent prognostic marker (Schindl et al, 2001, 2003;
Schoppmann et al, 2003). However, our data show that no
significance between Id-1 overexpression and the clinicopatholo-
gical biomarkers, such as survival rate, stage and tumour grade
although Id-1 overexpression is related with tumour angiogenesis
in pancreatic cancers. There are a number of possible explanations
for this discrepancy concerning the Id-1 role in the prognoses
between pancreatic cancer and other human cancers, such as
cervical and breast cancers. Because pancreatic cancer rapidly
progresses and is one of the most fatal malignant tumours, there is
no reliable prognostic marker except at the tumour stage.
Although it has been shown that human solid tumours have
heterogeneous MVD, comparatively higher counts at the invasive
edges of the tumours, and MVD is related with a poorer prognosis,
there is still controversy on the prognostic significance of MVD in
human pancreatic cancer because of its miserable clinicobiological
course (Ellis et al, 1998; Khan et al, 2002; Gasparini, 1997). The
other possible explanation is that Id-1 expression is tissue specific
and has a different role in the development of various tissues that
may contribute to different roles in carcinogenesis and in different
biologic behaviours of different human cancers (Riechmann et al,
1994; Riechmann and Sablitzky, 1995; Lyden et al, 1999; Norton,
2000). Nevertheless, our results suggest that Id-1 overexpression
does not have greater influence on the prognosis of human
pancreatic cancer than other important prognostic markers,
including stage and tumour grade.
In conclusion, our findings demonstrate the role of Id-1
overexpression in human primary pancreatic cancer. Id-1 over-
expression was found to be closely related to tumour angiogenesis,
a higher density of intratumoral vessel, but not with a poorer
survival or a higher cell proliferation potential in human
pancreatic cancer. This provides evidence that clarifies the
association between Id-1 overexpression and tumour angiogenesis
in human primary cancers and indicates Id-1 protein may be an
important new target molecule for antiangiogenic drug design in
cancer treatment. Additional studies are required to determine
whether Id-1 has a similar impact on tumour angiogenesis in other
human cancers.
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